2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.Peer-Reviewed Original ResearchConceptsHigh-dose groupLow-dose groupMedium-dose groupGeometric mean titresAdverse eventsRecombinant protein vaccineCOVID-19 vaccineSecond vaccinationSARS-CoV-2Day 36Antigen doseAdverse reactionsProtein vaccineMedical conditionsVaccine-related serious adverse eventsHigh-risk medical conditionsInteractive response technology systemAntibody geometric mean titresPre-existing medical conditionsCandidate vaccine formulationsCoV2 preS dTMPrevious phase 1Primary immunogenicity objectivePseudovirus neutralization assayUnsolicited adverse events
2007
A West Nile Virus Recombinant Protein Vaccine That Coactivates Innate and Adaptive Immunity
Huleatt J, Foellmer H, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi V, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell T, McDonald W. A West Nile Virus Recombinant Protein Vaccine That Coactivates Innate and Adaptive Immunity. The Journal Of Infectious Diseases 2007, 195: 1607-1617. PMID: 17471430, DOI: 10.1086/517613.Peer-Reviewed Original ResearchConceptsImmune responseAntibody responseImmunoglobulin G antibody responseC3H/HeN miceWest Nile virus vaccineAdaptive immune signalsTLR5-deficient miceAntigen-specific responsesG antibody responseProtective immune responseAdaptive immune responsesToll-like receptorsWNV envelope proteinLethal WNV challengeRecombinant protein vaccineInterleukin-8 productionNeutralized viral infectivityEnzyme-linked immunosorbentEffective WNV vaccinesWNV vaccineHeN miceVirus challengeProtein vaccineVirus vaccineWNV challenge
2006
Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2006, 25: 763-775. PMID: 16968658, DOI: 10.1016/j.vaccine.2006.08.013.Peer-Reviewed Original ResearchConceptsCD8 T cell responsesT cell responsesAntigen-specific responsesCell responsesRecombinant fusion proteinAntigen fusion proteinProtective CD8 T cell responsesAntigen-specific CD8 T-cell responsesPotent antigen-specific responsesToll-like receptor ligandsToll-like receptor (TLR) familyComplete Freund's adjuvantDay of immunizationB cell responsesTLR5 ligand flagellinImmunization of miceRecombinant protein vaccineVirulent L. monocytogenesSupplemental adjuvantsProtective immunityTLR ligandsFreund's adjuvantHumoral immunityProtein vaccineEnhanced immunogenicity
1990
Prophylactic Immunization against Experimental Leishmania donovani Infection by Use of a Purified Protein Vaccine
White A, McMahon-Pratt D. Prophylactic Immunization against Experimental Leishmania donovani Infection by Use of a Purified Protein Vaccine. The Journal Of Infectious Diseases 1990, 161: 1313-1314. PMID: 2345310, DOI: 10.1093/infdis/161.6.1313.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply